# ArriVent BioPharma, Inc.: overview AVBP · Nasdaq · CIK 1868279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/avbp.md) · [Financials](/companies/avbp/financials.md) · [Filings](/companies/avbp/filings.md) · [Insiders](/companies/avbp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.61)](/filings/0001104659-25-108847.md) | not reported | [(1.90)](/filings/0001104659-26-058650.md) | [(0.90)](/filings/0001104659-26-094902.md) | [(0.83)](/filings/0001104659-25-108847.md) | not reported | [(0.96)](/filings/0001104659-26-058650.md) | [(1.05)](/filings/0001104659-26-094902.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(32.38)](/filings/0001558370-25-001999.md) | [(2.56)](/filings/0001104659-26-024127.md) | [(4.32)](/filings/0001104659-26-024127.md) | | Free cash flow | $ | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avbp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $156.9m | 4,515,531 | | Added +114,448 | | [INFINITUM ASSET MANAGEMENT, LLC](/funds/2058093.md) | 2026-06-30 | $154.2m | 4,438,384 | | Added +289,461 | | [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $136.5m | 3,929,117 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $112.9m | 3,250,396 | | Added +720,095 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $105.2m | 3,027,328 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $96.5m | 2,778,959 | | Reduced −237,173 | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $68.5m | 1,971,054 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $61.7m | 1,774,873 | | Added +245,980 | | [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $58.9m | 1,696,752 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $58.8m | 1,692,986 | | Added +271,571 | ## Recent filings [All 153 filings](/companies/avbp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 06:00 ET | [8-K](/filings/0001104659-26-118550.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-118550 | | 2026-10-19 | 08:08 ET | [8-K](/filings/0001104659-26-116736.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-116736 | | 2026-10-13 | 06:03 ET | [8-K](/filings/0001104659-26-115161.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115161 | | 2026-10-08 | 18:39 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000931.md) | Ownership report, active investor, amended | 0000947871-26-000931 | | 2026-10-06 | 08:07 ET | [8-K](/filings/0001104659-26-113898.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113898 | | 2026-08-12 | 16:20 ET | [10-Q](/filings/0001104659-26-094902.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094902 | | 2026-08-12 | 16:07 ET | [8-K](/filings/0001104659-26-094869.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094869 | | 2026-06-22 | 16:01 ET | [8-K](/filings/0001104659-26-076352.md) | 5.07 Shareholder vote results | 0001104659-26-076352 | | 2026-05-11 | 16:43 ET | [8-K](/filings/0001104659-26-058706.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-058706 | | 2026-05-11 | 16:08 ET | [10-Q](/filings/0001104659-26-058650.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058650 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-024127.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1868279 - Tickers: AVBP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 06:02 ET. No prices; not investment advice.